Sterling Pharma Solutions, a global contract development and manufacturing organization, announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million investment to increase GMP bioconjugation capacity. A new 2,300-square foot suite is being commissioned to allow clinical-scale manufacturing using reactors up to 500 liters in volume, which will more than double the site’s existing capacity, and offer...